Cancer Pharmacology Division, Indian Institute of Integrative Medicine (Council of Scientific & Industrial Research), Jammu 180001, India ; Department of Pharmacology, Therapeutics & Toxicology (PTT), Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, PMB 12003, Lagos 23401, Nigeria.
Cancer Pharmacology Division, Indian Institute of Integrative Medicine (Council of Scientific & Industrial Research), Jammu 180001, India.
Evid Based Complement Alternat Med. 2015;2015:560404. doi: 10.1155/2015/560404. Epub 2015 Feb 24.
Introduction. Sansevieria liberica Gerome and Labroy (Agavaceae) is a perennial plant widely distributed in tropical Africa. Preparations of the plant are commonly used across Nigeria for the treatment of inflammatory conditions. Based on the fact that herbal medicine is a strong component of integrative medicine, this study was conducted to evaluate the anticancer activity of root extracts of Sansevieria liberica. Methods. Sulforhodamine B (SRB) in vitro cytotoxicity assay, Sarcoma-180 (S-180) ascites and solid tumor, and L1210 lymphoid leukemia in vivo models were used in this study. Results. SL-A002 (IC50 23 µg/mL with HeLa), SL-A003 (IC50 22 µg/mL with HCT-116), and SL-A004 (IC50 23 and 18 µg/mL with A549 and THP-1, resp.) demonstrated significant activity in the SRB cytotoxicity assay. Potency was highest with the following pairs of extract : cancer cell line: SL-A002 : HeLa (IC50 23 µg/mL), SL-A003 : HCT-116 (IC50 22 µg/mL), and SL-A004 : THP-1 (IC50 18 µg/mL). SL-A002 demonstrated significant dose-dependent antitumor activity in the Sarcoma-180 (S-180) ascites model with peak effect produced at the dose of 120 mg/kg (i.p.) with inhibition of 89.36% compared to 97.96% for 5-FU (20 mg/kg i.p.). The inhibition of tumor growth by SL-A002 in the S-180 solid tumor model was 47.40% compared to a value of 50.18% for 5-FU. SL-A002 was also significantly active in the L1210 lymphoid leukemia model with 158.33% increase in mean survival time, the same value for 5-FU. Conclusions. The hydroethanolic extract of Sansevieria liberica, SL-A002, possesses significant anticancer activity to warrant further extensive study to identify, isolate, and characterize the specific bioactive molecules responsible for the observed antitumor activity and the precise mechanism(s) of action.
简介。利比里亚蛇尾兰（龙舌兰科）是一种广泛分布于热带非洲的多年生植物。该植物的制剂在尼日利亚被广泛用于治疗炎症性疾病。基于草药是综合医学的重要组成部分这一事实，本研究旨在评估利比里亚蛇尾兰根提取物的抗癌活性。
方法。本研究采用磺酰罗丹明 B（SRB）体外细胞毒性试验、肉瘤 180（S-180）腹水和实体瘤以及 L1210 淋巴白血病体内模型。
结果。SL-A002（对 HeLa 的 IC50 为 23μg/mL）、SL-A003（对 HCT-116 的 IC50 为 22μg/mL）和 SL-A004（对 A549 和 THP-1 的 IC50 分别为 23 和 18μg/mL）在 SRB 细胞毒性试验中表现出显著的活性。提取物与癌细胞系的活性最高的组合为：SL-A002：HeLa（IC50 为 23μg/mL）、SL-A003：HCT-116（IC50 为 22μg/mL）和 SL-A004：THP-1（IC50 为 18μg/mL）。SL-A002 在肉瘤 180（S-180）腹水模型中表现出显著的剂量依赖性抗肿瘤活性，在 120mg/kg（ip）剂量下产生峰值效应，抑制率为 89.36%，而 5-FU（20mg/kg ip）的抑制率为 97.96%。SL-A002 在 S-180 实体瘤模型中的肿瘤生长抑制率为 47.40%，而 5-FU 的抑制率为 50.18%。SL-A002 在 L1210 淋巴白血病模型中也表现出显著的活性，平均存活时间增加 158.33%，与 5-FU 相同。
结论。利比里亚蛇尾兰的水醇提取物 SL-A002 具有显著的抗癌活性，值得进一步广泛研究，以确定、分离和表征负责观察到的抗肿瘤活性的特定生物活性分子以及确切的作用机制。
